An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

PHASE3RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2026

Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
DRUG

Aficamten

5-20mg

Trial Locations (12)

Unknown

NOT_YET_RECRUITING

Beijing Anzhen Hospital, Beijing

RECRUITING

Beijing Chao-yang Hospital, Capital Medical University, Beijing

RECRUITING

Fuwai Hospital, CAMS & PUMC, Beijing

RECRUITING

Peking University Third Hospital, Beijing

NOT_YET_RECRUITING

Sichuan Provincial People's Hospital, Chengdu

NOT_YET_RECRUITING

Nanfang Hospital, Guangzhou

RECRUITING

The Second Affiliated Hospital of Nanchang University, Jiangxi

RECRUITING

The First Hospital of Jilin University, Jilin

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

RECRUITING

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Sponsors
All Listed Sponsors
lead

Corxel Pharmaceuticals

INDUSTRY

NCT06116968 - An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM | Biotech Hunter | Biotech Hunter